Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 14, 2026
Alaunos Therapeutics, Inc. (TCRT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $952,000.
Revenue
$0
Net income
$-952,000
+9.4% vs year-ago quarter
Operating cash flow
$-300,000
+57.2% vs year-ago quarter
Free cash flow
$-553,000
+6.6% vs year-ago quarter
EPS
$-0.41
+34.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.54M
+15.7% vs year-ago quarter
Net cash
$1.09M
Q4 FY2024
Operating margin
-135233.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TCRT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1107421
- Former names
- ZIOPHARM ONCOLOGY INC (until Jan 4, 2022); EASYWEB INC (until Sep 19, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3,000 | $0 | $0 |
| Operating income | -$952,000 | -$1.0M | -$907,000 | -$1.2M | -$1.0M |
| Net income | -$952,000 | -$1.0M | -$893,000 | -$1.2M | -$1.1M |
| Diluted EPS | -$0.41 | -$0.59 | -$0.40 | -$0.55 | -$0.63 |
| Operating cash flow | -$300,000 | -$1.0M | -$552,000 | -$844,000 | -$701,000 |
| Free cash flow | — | — | -$553,000 | -$941,000 | — |
| Total assets | $1.5M | $1.9M | $3.0M | $3.7M | $4.7M |
| Total liabilities | $864,000 | $595,000 | $813,000 | $921,000 | $1.1M |
| Stockholders' equity | $652,000 | $1.3M | $2.2M | $2.8M | $3.7M |
| Cash and investments | $124,000 | $354,000 | $1.4M | $1.9M | $2.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 9, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 22, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 17, 2026 | Sep 16, 2026 |
All 1000 Alaunos Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.